S. Hüttner

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase‐4 inhibitor in male type 2 diabetes patients

Tim Heise, Eva U. Graefe-Mody, S. Hüttner et al. · Diabetes Obesity and Metabolism · 2009 · 174 citations

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers

S. Hüttner, Eva U. Graefe-Mody, B. Withopf et al. · The Journal of Clinical Pharmacology · 2008 · 133 citations

Pharmacotherapy, Single Oral Doses, Adverse Drug Reaction +18

Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5 mg–10 mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in Healthy Male Subjects

Silke Retlich, Vincent Duval, Arne Ring et al. · Clinical Pharmacokinetics · 2010 · 48 citations

Molecular Pharmacology, Therapeutic Drug Monitoring, Pharmacokinetic Modeling +11

Phase 1 and 2 Randomized Clinical Studies Determine Lack of Efficacy for Anti-IL-17C Antibody MOR106 in Moderate–Severe Atopic Dermatitis

Diamant Thaçi, Dave Singh, Mark S. Lee et al. · Journal of Clinical Medicine · 2022 · 10 citations · Full text